Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction
BACKGROUND:Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI. METHODS:We investigated the effects of administrating 33,000 IU EPO on the occurrence of post-MI...
Gespeichert in:
| Veröffentlicht in: | Journal of cardiovascular pharmacology 2015-06, Vol.65 (6), p.555-561 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 561 |
|---|---|
| container_issue | 6 |
| container_start_page | 555 |
| container_title | Journal of cardiovascular pharmacology |
| container_volume | 65 |
| creator | Gholamzadeh, Ali Amini, Sara Mohammadpour, Amir H Vahabzadeh, Maryam Fazelifar, Amir F Fazlinezhad, Afsoon Dehghani, Mashalla Moohebati, Mohsen Dastani, Mostafa Malaekeh-Nikouie, Bizhan Falsoleiman, Homa |
| description | BACKGROUND:Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI.
METHODS:We investigated the effects of administrating 33,000 IU EPO on the occurrence of post-MI arrhythmia in 40 patients with ST-elevation MI who were randomly assigned in either EPO or placebo groups. Arrhythmias were blindly documented using full 12-lead configuration during 24 hours after percutaneous coronary intervention (PCI) by a cardiologist. Afterward, CK-MB, hematologic, and hemodynamic data were examined within 2 weeks after MI.
RESULTS:A comparison made between the 2 groups showed significant differences in the incidence of arrhythmias (20% in EPO group and 35% in placebo group, P = 0.043). However, no significant differences in type of arrhythmias were observed between the groups. There was no significant difference between levels of CK-MB in the 2 groups during 24 hours (P = 0.186). Hematologic and hemodynamic data showed no significant changes 2 weeks after PCI.
CONCLUSION:High-dose administration of EPO in patients with ST-elevation MI who have been treated by primary PCI and standard antiplatelet therapy reduces the occurrence of arrhythmias. For clinical interpretation of the results, further well-designed trials are required. |
| doi_str_mv | 10.1097/FJC.0000000000000223 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4461390</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>25636071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5273-e6347bf7f19062170d32c361db9a60a21661f8874cf8d6dc3fd65b5b890976aa3</originalsourceid><addsrcrecordid>eNp9kN9OwjAUxhujEUTfwJi-wLB_tm67MSFEFIORKMbLpms7Vx0raQeEt7cEJeiF5-Yk53zfd05-AFxi1McoT69HD8M-OixC6BHo4oTSKEaEHoMuwgxFJI5ZB5x5_4EQjpOUnYIOSRhlKMVdwG_dpq2cXVijW9PAZ62WUns4tb6NpsMxHDhXBcXcCA_Dfipao5vWwzfTVvBlFular8LMNvBxY6VwyogajptSOLmdnoOTUtReX3z3Hngd3c6G99Hk6W48HEwimZCURprROC3KtMQ5YgSnSFEiKcOqyAVDgmDGcJllaSzLTDElaalYUiRFlgcUTAjaAze73MWymGslw49O1HzhzFy4DbfC8N-bxlT83a54oINpjkJAvAuQznrvdLn3YsS3wHkAzv8CD7arw7t70w_hIMh2grWtW-38Z71ca8crLeq2-j_7Cym_jkw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Gholamzadeh, Ali ; Amini, Sara ; Mohammadpour, Amir H ; Vahabzadeh, Maryam ; Fazelifar, Amir F ; Fazlinezhad, Afsoon ; Dehghani, Mashalla ; Moohebati, Mohsen ; Dastani, Mostafa ; Malaekeh-Nikouie, Bizhan ; Falsoleiman, Homa</creator><creatorcontrib>Gholamzadeh, Ali ; Amini, Sara ; Mohammadpour, Amir H ; Vahabzadeh, Maryam ; Fazelifar, Amir F ; Fazlinezhad, Afsoon ; Dehghani, Mashalla ; Moohebati, Mohsen ; Dastani, Mostafa ; Malaekeh-Nikouie, Bizhan ; Falsoleiman, Homa</creatorcontrib><description>BACKGROUND:Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI.
METHODS:We investigated the effects of administrating 33,000 IU EPO on the occurrence of post-MI arrhythmia in 40 patients with ST-elevation MI who were randomly assigned in either EPO or placebo groups. Arrhythmias were blindly documented using full 12-lead configuration during 24 hours after percutaneous coronary intervention (PCI) by a cardiologist. Afterward, CK-MB, hematologic, and hemodynamic data were examined within 2 weeks after MI.
RESULTS:A comparison made between the 2 groups showed significant differences in the incidence of arrhythmias (20% in EPO group and 35% in placebo group, P = 0.043). However, no significant differences in type of arrhythmias were observed between the groups. There was no significant difference between levels of CK-MB in the 2 groups during 24 hours (P = 0.186). Hematologic and hemodynamic data showed no significant changes 2 weeks after PCI.
CONCLUSION:High-dose administration of EPO in patients with ST-elevation MI who have been treated by primary PCI and standard antiplatelet therapy reduces the occurrence of arrhythmias. For clinical interpretation of the results, further well-designed trials are required.</description><identifier>ISSN: 0160-2446</identifier><identifier>EISSN: 1533-4023</identifier><identifier>DOI: 10.1097/FJC.0000000000000223</identifier><identifier>PMID: 25636071</identifier><language>eng</language><publisher>United States: Copyright Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Adult ; Anti-Arrhythmia Agents - administration & dosage ; Anti-Arrhythmia Agents - adverse effects ; Arrhythmias, Cardiac - diagnosis ; Arrhythmias, Cardiac - etiology ; Arrhythmias, Cardiac - physiopathology ; Arrhythmias, Cardiac - prevention & control ; Biomarkers - blood ; Creatine Kinase, MB Form - blood ; Electrocardiography ; Erythropoietin - administration & dosage ; Erythropoietin - adverse effects ; Female ; Hemodynamics - drug effects ; Humans ; Iran ; Male ; Middle Aged ; Myocardial Infarction - complications ; Myocardial Infarction - diagnosis ; Myocardial Infarction - physiopathology ; Myocardial Infarction - therapy ; Original ; Percutaneous Coronary Intervention - adverse effects ; Pilot Projects ; Platelet Aggregation Inhibitors - therapeutic use ; Recombinant Proteins - administration & dosage ; Risk Factors ; Time Factors ; Treatment Outcome</subject><ispartof>Journal of cardiovascular pharmacology, 2015-06, Vol.65 (6), p.555-561</ispartof><rights>Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5273-e6347bf7f19062170d32c361db9a60a21661f8874cf8d6dc3fd65b5b890976aa3</citedby><cites>FETCH-LOGICAL-c5273-e6347bf7f19062170d32c361db9a60a21661f8874cf8d6dc3fd65b5b890976aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25636071$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gholamzadeh, Ali</creatorcontrib><creatorcontrib>Amini, Sara</creatorcontrib><creatorcontrib>Mohammadpour, Amir H</creatorcontrib><creatorcontrib>Vahabzadeh, Maryam</creatorcontrib><creatorcontrib>Fazelifar, Amir F</creatorcontrib><creatorcontrib>Fazlinezhad, Afsoon</creatorcontrib><creatorcontrib>Dehghani, Mashalla</creatorcontrib><creatorcontrib>Moohebati, Mohsen</creatorcontrib><creatorcontrib>Dastani, Mostafa</creatorcontrib><creatorcontrib>Malaekeh-Nikouie, Bizhan</creatorcontrib><creatorcontrib>Falsoleiman, Homa</creatorcontrib><title>Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction</title><title>Journal of cardiovascular pharmacology</title><addtitle>J Cardiovasc Pharmacol</addtitle><description>BACKGROUND:Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI.
METHODS:We investigated the effects of administrating 33,000 IU EPO on the occurrence of post-MI arrhythmia in 40 patients with ST-elevation MI who were randomly assigned in either EPO or placebo groups. Arrhythmias were blindly documented using full 12-lead configuration during 24 hours after percutaneous coronary intervention (PCI) by a cardiologist. Afterward, CK-MB, hematologic, and hemodynamic data were examined within 2 weeks after MI.
RESULTS:A comparison made between the 2 groups showed significant differences in the incidence of arrhythmias (20% in EPO group and 35% in placebo group, P = 0.043). However, no significant differences in type of arrhythmias were observed between the groups. There was no significant difference between levels of CK-MB in the 2 groups during 24 hours (P = 0.186). Hematologic and hemodynamic data showed no significant changes 2 weeks after PCI.
CONCLUSION:High-dose administration of EPO in patients with ST-elevation MI who have been treated by primary PCI and standard antiplatelet therapy reduces the occurrence of arrhythmias. For clinical interpretation of the results, further well-designed trials are required.</description><subject>Adult</subject><subject>Anti-Arrhythmia Agents - administration & dosage</subject><subject>Anti-Arrhythmia Agents - adverse effects</subject><subject>Arrhythmias, Cardiac - diagnosis</subject><subject>Arrhythmias, Cardiac - etiology</subject><subject>Arrhythmias, Cardiac - physiopathology</subject><subject>Arrhythmias, Cardiac - prevention & control</subject><subject>Biomarkers - blood</subject><subject>Creatine Kinase, MB Form - blood</subject><subject>Electrocardiography</subject><subject>Erythropoietin - administration & dosage</subject><subject>Erythropoietin - adverse effects</subject><subject>Female</subject><subject>Hemodynamics - drug effects</subject><subject>Humans</subject><subject>Iran</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - complications</subject><subject>Myocardial Infarction - diagnosis</subject><subject>Myocardial Infarction - physiopathology</subject><subject>Myocardial Infarction - therapy</subject><subject>Original</subject><subject>Percutaneous Coronary Intervention - adverse effects</subject><subject>Pilot Projects</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Risk Factors</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0160-2446</issn><issn>1533-4023</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kN9OwjAUxhujEUTfwJi-wLB_tm67MSFEFIORKMbLpms7Vx0raQeEt7cEJeiF5-Yk53zfd05-AFxi1McoT69HD8M-OixC6BHo4oTSKEaEHoMuwgxFJI5ZB5x5_4EQjpOUnYIOSRhlKMVdwG_dpq2cXVijW9PAZ62WUns4tb6NpsMxHDhXBcXcCA_Dfipao5vWwzfTVvBlFular8LMNvBxY6VwyogajptSOLmdnoOTUtReX3z3Hngd3c6G99Hk6W48HEwimZCURprROC3KtMQ5YgSnSFEiKcOqyAVDgmDGcJllaSzLTDElaalYUiRFlgcUTAjaAze73MWymGslw49O1HzhzFy4DbfC8N-bxlT83a54oINpjkJAvAuQznrvdLn3YsS3wHkAzv8CD7arw7t70w_hIMh2grWtW-38Z71ca8crLeq2-j_7Cym_jkw</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Gholamzadeh, Ali</creator><creator>Amini, Sara</creator><creator>Mohammadpour, Amir H</creator><creator>Vahabzadeh, Maryam</creator><creator>Fazelifar, Amir F</creator><creator>Fazlinezhad, Afsoon</creator><creator>Dehghani, Mashalla</creator><creator>Moohebati, Mohsen</creator><creator>Dastani, Mostafa</creator><creator>Malaekeh-Nikouie, Bizhan</creator><creator>Falsoleiman, Homa</creator><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><general>Journal of Cardiovascular Pharmacology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>201506</creationdate><title>Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction</title><author>Gholamzadeh, Ali ; Amini, Sara ; Mohammadpour, Amir H ; Vahabzadeh, Maryam ; Fazelifar, Amir F ; Fazlinezhad, Afsoon ; Dehghani, Mashalla ; Moohebati, Mohsen ; Dastani, Mostafa ; Malaekeh-Nikouie, Bizhan ; Falsoleiman, Homa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5273-e6347bf7f19062170d32c361db9a60a21661f8874cf8d6dc3fd65b5b890976aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Anti-Arrhythmia Agents - administration & dosage</topic><topic>Anti-Arrhythmia Agents - adverse effects</topic><topic>Arrhythmias, Cardiac - diagnosis</topic><topic>Arrhythmias, Cardiac - etiology</topic><topic>Arrhythmias, Cardiac - physiopathology</topic><topic>Arrhythmias, Cardiac - prevention & control</topic><topic>Biomarkers - blood</topic><topic>Creatine Kinase, MB Form - blood</topic><topic>Electrocardiography</topic><topic>Erythropoietin - administration & dosage</topic><topic>Erythropoietin - adverse effects</topic><topic>Female</topic><topic>Hemodynamics - drug effects</topic><topic>Humans</topic><topic>Iran</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - complications</topic><topic>Myocardial Infarction - diagnosis</topic><topic>Myocardial Infarction - physiopathology</topic><topic>Myocardial Infarction - therapy</topic><topic>Original</topic><topic>Percutaneous Coronary Intervention - adverse effects</topic><topic>Pilot Projects</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Risk Factors</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gholamzadeh, Ali</creatorcontrib><creatorcontrib>Amini, Sara</creatorcontrib><creatorcontrib>Mohammadpour, Amir H</creatorcontrib><creatorcontrib>Vahabzadeh, Maryam</creatorcontrib><creatorcontrib>Fazelifar, Amir F</creatorcontrib><creatorcontrib>Fazlinezhad, Afsoon</creatorcontrib><creatorcontrib>Dehghani, Mashalla</creatorcontrib><creatorcontrib>Moohebati, Mohsen</creatorcontrib><creatorcontrib>Dastani, Mostafa</creatorcontrib><creatorcontrib>Malaekeh-Nikouie, Bizhan</creatorcontrib><creatorcontrib>Falsoleiman, Homa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cardiovascular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gholamzadeh, Ali</au><au>Amini, Sara</au><au>Mohammadpour, Amir H</au><au>Vahabzadeh, Maryam</au><au>Fazelifar, Amir F</au><au>Fazlinezhad, Afsoon</au><au>Dehghani, Mashalla</au><au>Moohebati, Mohsen</au><au>Dastani, Mostafa</au><au>Malaekeh-Nikouie, Bizhan</au><au>Falsoleiman, Homa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction</atitle><jtitle>Journal of cardiovascular pharmacology</jtitle><addtitle>J Cardiovasc Pharmacol</addtitle><date>2015-06</date><risdate>2015</risdate><volume>65</volume><issue>6</issue><spage>555</spage><epage>561</epage><pages>555-561</pages><issn>0160-2446</issn><eissn>1533-4023</eissn><abstract>BACKGROUND:Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI.
METHODS:We investigated the effects of administrating 33,000 IU EPO on the occurrence of post-MI arrhythmia in 40 patients with ST-elevation MI who were randomly assigned in either EPO or placebo groups. Arrhythmias were blindly documented using full 12-lead configuration during 24 hours after percutaneous coronary intervention (PCI) by a cardiologist. Afterward, CK-MB, hematologic, and hemodynamic data were examined within 2 weeks after MI.
RESULTS:A comparison made between the 2 groups showed significant differences in the incidence of arrhythmias (20% in EPO group and 35% in placebo group, P = 0.043). However, no significant differences in type of arrhythmias were observed between the groups. There was no significant difference between levels of CK-MB in the 2 groups during 24 hours (P = 0.186). Hematologic and hemodynamic data showed no significant changes 2 weeks after PCI.
CONCLUSION:High-dose administration of EPO in patients with ST-elevation MI who have been treated by primary PCI and standard antiplatelet therapy reduces the occurrence of arrhythmias. For clinical interpretation of the results, further well-designed trials are required.</abstract><cop>United States</cop><pub>Copyright Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>25636071</pmid><doi>10.1097/FJC.0000000000000223</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0160-2446 |
| ispartof | Journal of cardiovascular pharmacology, 2015-06, Vol.65 (6), p.555-561 |
| issn | 0160-2446 1533-4023 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4461390 |
| source | MEDLINE; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Anti-Arrhythmia Agents - administration & dosage Anti-Arrhythmia Agents - adverse effects Arrhythmias, Cardiac - diagnosis Arrhythmias, Cardiac - etiology Arrhythmias, Cardiac - physiopathology Arrhythmias, Cardiac - prevention & control Biomarkers - blood Creatine Kinase, MB Form - blood Electrocardiography Erythropoietin - administration & dosage Erythropoietin - adverse effects Female Hemodynamics - drug effects Humans Iran Male Middle Aged Myocardial Infarction - complications Myocardial Infarction - diagnosis Myocardial Infarction - physiopathology Myocardial Infarction - therapy Original Percutaneous Coronary Intervention - adverse effects Pilot Projects Platelet Aggregation Inhibitors - therapeutic use Recombinant Proteins - administration & dosage Risk Factors Time Factors Treatment Outcome |
| title | Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T13%3A17%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Erythropoietin%20Reduces%20Post-PCI%20Arrhythmias%20in%20Patients%20With%20ST-elevation%20Myocardial%20Infarction&rft.jtitle=Journal%20of%20cardiovascular%20pharmacology&rft.au=Gholamzadeh,%20Ali&rft.date=2015-06&rft.volume=65&rft.issue=6&rft.spage=555&rft.epage=561&rft.pages=555-561&rft.issn=0160-2446&rft.eissn=1533-4023&rft_id=info:doi/10.1097/FJC.0000000000000223&rft_dat=%3Cpubmed_cross%3E25636071%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/25636071&rfr_iscdi=true |